42
IRUS Total
Downloads

Untargeted mass spectrometry lipidomics identifies correlation between serum sphingomyelins and plasma cholesterol

Title: Untargeted mass spectrometry lipidomics identifies correlation between serum sphingomyelins and plasma cholesterol
Authors: Zalloua, P
Kadar, H
Hariri, E
Farraj, LA
Brial, F
Hedjazi, L
Le Lay, A
Colleu, A
Dubus, J
Touboul, D
Matsuda, F
Lathrop, M
Nicholson, JK
Dumas, M-E
Gauguier, D
Item Type: Journal Article
Abstract: Background Lipoproteins are major players in the development and progression of atherosclerotic plaques leading to coronary stenosis and myocardial infarction. Epidemiological, genetic and experimental observations have implicated the association of sphingolipids and intermediates of sphingolipid synthesis in atherosclerosis. We aimed to investigate relationships between quantitative changes in serum sphingolipids, the regulation of the metabolism of lipoproteins (LDL, HDL), and endophenotypes of coronary artery disease (CAD). Methods We carried out untargeted liquid chromatography – mass spectrometry (UPLC-MS) lipidomics of serum samples of subjects belonging to a cross-sectional study and recruited on the basis of absence or presence of angiographically-defined CAD, and extensively characterized for clinical and biochemical phenotypes. Results Among the 2998 spectral features detected in the serum samples, 1328 metabolic features were significantly correlated with at least one of the clinical or biochemical phenotypes measured in the cohort. We found evidence of significant associations between 34 metabolite signals, corresponding to a set of sphingomyelins, and serum HDL cholesterol. Many of these metabolite associations were also observed with serum LDL and total cholesterol levels but not as much with serum triglycerides. Conclusion Among patients with CAD, sphingolipids in the form of sphingomyelins are directly correlated with serum levels of lipoproteins and total cholesterol. Results from this study support the fundamental role of sphingolipids in modulating lipid serum levels, highlighting the importance to identify novel targets in the sphingolipid metabolic pathway for anti-atherogenic therapies.
Issue Date: 2-Feb-2019
Date of Acceptance: 17-Dec-2018
URI: http://hdl.handle.net/10044/1/68186
DOI: https://dx.doi.org/10.1186/s12944-018-0948-5
ISSN: 1476-511X
Publisher: BioMed Central
Journal / Book Title: Lipids in Health and Disease
Volume: 18
Issue: 1
Copyright Statement: © 2019 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Nutrition & Dietetics
Lipidomics
Lipoproteins
HDL cholesterol
Sphingolipids
UPLC-MS
CORONARY-HEART-DISEASE
ARTERY-DISEASE
RISK-FACTOR
LARGE-SCALE
METABOLISM
TOXICITY
1101 Medical Biochemistry And Metabolomics
0899 Other Information And Computing Sciences
Publication Status: Published
Article Number: 38
Online Publication Date: 2019-02-02
Appears in Collections:Department of Surgery and Cancer